Skip to main content
. Author manuscript; available in PMC: 2021 Feb 19.
Published in final edited form as: Neurochem Res. 2017 Mar 16;42(7):1904–1918. doi: 10.1007/s11064-017-2227-7

Fig. 1.

Fig. 1

Revised testing approach for the validation of the screening of investigational compounds by the ETSP. *Prototype compounds were presently screened for efficacy only in Identification phase assays. The most promising compounds would be candidates to advance to more advanced, labor-intensive etiologically-relevant models of disease, including the LTG-resistant amygdala-kindled rat or mouse model of mesial temporal lobe epilepsy